Universe Pharmaceuticals (NASDAQ:UPC) Stock Price Down 3.5% – Time to Sell?

Universe Pharmaceuticals INC (NASDAQ:UPC)’s share price dropped 3.5% during mid-day trading on Monday . The company traded as low as $4.13 and last traded at $4.16. Approximately 21,057 shares changed hands during trading, a decline of 90% from the average daily volume of 204,361 shares. The stock had previously closed at $4.31.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Universe Pharmaceuticals in a research note on Wednesday, October 8th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock currently has a consensus rating of “Sell”.

Universe Pharmaceuticals Stock Performance

The stock’s 50 day moving average is $3.93 and its two-hundred day moving average is $4.11.

Universe Pharmaceuticals Company Profile

Universe Pharmaceuticals, Inc is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics for ocular diseases. The company’s primary research efforts center on small-molecule compounds designed to address unmet needs in glaucoma, ocular hypertension and post-surgical ocular inflammation. By leveraging targeted enzyme inhibition and proprietary formulation technologies, Universe aims to bring forward topically administered medications that combine efficacy with an improved safety profile versus existing treatments.

The company’s lead candidate, UPC-1001, has been advanced into clinical trials for the treatment of open-angle glaucoma and ocular hypertension, where it seeks to lower intraocular pressure through a unique mechanism of action.